Intestinal Benign Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Intestinal Benign Neoplasm

MalaCards integrated aliases for Intestinal Benign Neoplasm:

Name: Intestinal Benign Neoplasm 12 15
Intestinal Neoplasms 43 71
Neoplasm of Intestinal Tract 12
Intestinal Tumors 12
Intestine Growth 12


External Ids:

Disease Ontology 12 DOID:4610
MeSH 43 D007414
NCIt 49 C3141
SNOMED-CT 67 126769007
UMLS 71 C0021841

Summaries for Intestinal Benign Neoplasm

Disease Ontology : 12 A gastrointestinal system benign neoplasm that is located in the intestine.

MalaCards based summary : Intestinal Benign Neoplasm, also known as intestinal neoplasms, is related to colorectal adenoma and gastric cancer, and has symptoms including constipation and diarrhea. An important gene associated with Intestinal Benign Neoplasm is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Glucagon and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include intestine, testes and colon.

Related Diseases for Intestinal Benign Neoplasm

Diseases related to Intestinal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 colorectal adenoma 32.4 TP53 MUTYH MIR21 MIR17 MIR15A KRAS
2 gastric cancer 32.3 TP53 MUTYH MIR21 MIR20A MIR192 MIR17
3 colonic benign neoplasm 32.2 TP53 MIR20A MIR18A MIR15A MIR143 KRAS
4 adenoma 31.5 TP53 MUTYH KRAS CTNNB1 APC
5 adenocarcinoma 31.3 TP53 KRAS HRAS CTNNB1 APC
6 familial adenomatous polyposis 31.3 TP53 MUTYH KRAS HRAS CTNNB1 APC
7 small intestine cancer 31.0 TP53 MUTYH KRAS HRAS CTNNB1
8 endometriosis 30.4 TP53 MIR20A MIR145 MIR143 MIR142
9 duodenum cancer 30.4 TP53 MUTYH KRAS HRAS
10 colon adenocarcinoma 30.4 TP53 MIR21 KRAS CTNNB1 APC
11 peutz-jeghers syndrome 30.4 TP53 CTNNB1 APC
12 desmoid tumor 30.4 MUTYH CTNNB1 APC
13 peptic ulcer disease 30.2 TP53 HRAS H2AC18
14 pancreatitis 30.2 TP53 MIR21 KRAS HRAS
15 colorectal cancer 30.1 TP53 MUTYH MIR21 MIR20A MIR192 MIR18A
16 lynch syndrome 29.8 TP53 MUTYH MIR532 MIR17 KRAS HRAS
17 gastrointestinal system cancer 29.8 MIR532 MIR21 MIR20A MIR192 MIR18A MIR17
18 myeloma, multiple 29.7 TP53 MIR21 MIR17 MIR15A MIR145 MIR142
19 esophageal cancer 29.7 TP53 MIR21 MIR192 MIR145 MIR143 MIR142
20 rectum cancer 29.7 MUTYH MIR21 MIR20A MIR192 MIR17 MIR145
21 gastric adenocarcinoma 29.6 TP53 KRAS HRAS CTNNB1 APC
22 gastrointestinal system disease 29.5 MIR532 MIR21 MIR20A MIR192 MIR18A MIR17
23 pancreatic cancer 29.3 TP53 MIR21 MIR20A MIR17 MIR15A MIR145
24 intestinal disease 29.3 TP53 MIR532 MIR21 MIR20A MIR192 MIR18A
25 small intestine benign neoplasm 12.4
26 large intestine adenoma 11.2
27 cecal benign neoplasm 11.2
28 small intestine leiomyoma 11.2
29 large bowel leiomyoma 11.2
30 large intestine lipoma 11.2
31 rare tumor of intestine 11.1
32 omphalocele 11.0
33 feingold syndrome 1 10.7 MIR20A MIR18A MIR17
34 ampulla of vater neoplasm 10.7 KRAS HRAS APC
35 periampullary adenoma 10.7 KRAS HRAS APC
36 signet ring basal cell carcinoma 10.7 KRAS HRAS
37 trachea carcinoma in situ 10.7 KRAS HRAS
38 cobblestone retinal degeneration 10.7 KRAS HRAS
39 attenuated familial adenomatous polyposis 10.7 MUTYH APC
40 hepatic flexure cancer 10.7 KRAS APOLD1
41 vulvar intraepithelial neoplasia 10.7 TP53 CTNNB1
42 anal squamous cell carcinoma 10.7 TP53 APOLD1 APC
43 nasal cavity adenocarcinoma 10.7 KRAS HRAS
44 prostate squamous cell carcinoma 10.7 TP53 HRAS
45 descending colon cancer 10.7 KRAS HRAS APOLD1
46 familial colorectal cancer 10.7 MUTYH APC
47 coronavirus infectious disease 10.7 MIR17 H2AC18 CCR6
48 ascending colon cancer 10.7 KRAS HRAS APOLD1
49 duodenal benign neoplasm 10.7 HRAS APC
50 endometrioid ovary carcinoma 10.7 TP53 KRAS CTNNB1

Graphical network of the top 20 diseases related to Intestinal Benign Neoplasm:

Diseases related to Intestinal Benign Neoplasm

Symptoms & Phenotypes for Intestinal Benign Neoplasm

UMLS symptoms related to Intestinal Benign Neoplasm:

constipation, diarrhea

Drugs & Therapeutics for Intestinal Benign Neoplasm

Drugs for Intestinal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 220)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Glucagon Approved Phase 4 16941-32-5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Bisacodyl Approved Phase 4 603-50-9
4 Glucagon-Like Peptide 1 Phase 4
5 Fibrinolytic Agents Phase 4
6 Analgesics, Non-Narcotic Phase 4
7 Platelet Aggregation Inhibitors Phase 4
8 Cyclooxygenase Inhibitors Phase 4
9 Antipyretics Phase 4
10 Anti-Inflammatory Agents, Non-Steroidal Phase 4
11 Laxatives Phase 4
12 Cathartics Phase 4
13 glutamine Phase 4
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
17 Orange Approved Phase 3
Simvastatin Approved Phase 3 79902-63-9 54454
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
Ondansetron Approved Phase 3 99614-02-5 4595
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
Ofloxacin Approved Phase 3 82419-36-1 4583
Morphine Approved, Investigational Phase 3 57-27-2 5288826
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
Bevacizumab Approved, Investigational Phase 3 216974-75-3
29 Amoxicillin-Potassium Clavulanate Combination Phase 3
30 beta-Lactamase Inhibitors Phase 3
31 Anti-Bacterial Agents Phase 3
32 Gastrointestinal Agents Phase 3
33 Hypolipidemic Agents Phase 3
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
35 Anticholesteremic Agents Phase 3
36 Lipid Regulating Agents Phase 3
37 Calcium, Dietary Phase 3
38 Analgesics Phase 3
39 Cyclooxygenase 2 Inhibitors Phase 2, Phase 3
40 Anti-Infective Agents Phase 3
41 Hematinics Phase 3
42 Epoetin alfa Phase 3 113427-24-0
43 Dermatologic Agents Phase 3
44 Neurotransmitter Agents Phase 3
45 Antiemetics Phase 3
46 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
47 Anti-Anxiety Agents Phase 3
48 Psychotropic Drugs Phase 3
49 Antipsychotic Agents Phase 3
50 Cytochrome P-450 Enzyme Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
2 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
3 Phase 4 Study of Comparison of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection. A Prospective Randomized Controlled Trial. Completed NCT01887158 Phase 4 Polyethylene glycol;Bisacodyl
4 The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study Completed NCT01552291 Phase 4 Placebo
5 A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Unknown status NCT03303495 Phase 3 CPT-11;5-FU Bolus;5-FU Infusion;l-LV (dl-LV)
6 Impact of [68 Ga]-DOTANOC PET-CT on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Prospective, Multicentric Study. Unknown status NCT02608203 Phase 2, Phase 3 [68Ga]-DOTANOC PET/CT
7 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Intestinal Cancer Completed NCT03350490 Phase 2, Phase 3 Life information rehabilitation therapy
9 Prospective, Double-Blinded, Multi-Centred, Randomised Controlled Trial of Perioperative Simvastatin Use in Elective Colorectal Surgery Completed NCT00994903 Phase 3 Simvastatin;Placebo
10 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
11 A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer Completed NCT01996306 Phase 3 CPT-11 (Irinotecan);5-FU Bolus;5-FU Infusion;l-LV (dl-LV);CPT-11 (Irinotecan);Capecitabine
12 A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy Completed NCT00003600 Phase 3
13 Randomized Trial Comparing Drainage Versus no Drainage Following Rectal Excision With Low Anastomosis for Rectal Cancer Completed NCT01269567 Phase 3
14 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
15 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
16 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
17 A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Recruiting NCT03464305 Phase 3 acetylsalicylic acid;Placebo
18 Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
19 A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC). Active, not recruiting NCT02753127 Phase 3 Napabucasin;Fluorouracil;Leucovorin;Irinotecan;Bevacizumab
20 Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
21 A Single Group, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 Unknown status NCT03457844 Phase 2 Anlotinib
22 Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery Unknown status NCT02202928 Phase 2 Chemotherapy
23 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
24 A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
25 A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
26 An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer Completed NCT01397305 Phase 1, Phase 2 [6R] 5,10-methylenetetrahydrofolate;Pemetrexed
27 Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol. Completed NCT02241499 Phase 2 Oxaliplatin and fluorouracil.
28 Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer Completed NCT01016639 Phase 1, Phase 2
29 Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas Completed NCT00005874 Phase 2 rubitecan
30 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
31 A Single-Blind, Randomized Phase I/II Study of Pharmacokinetic and Pharmacodynamic Investigation of Modufolin® (60 or 200mg/m2) Compared to Levoleucovorin (60 or 200mg/m2) in Tumor, Adjacent Mucosa and Plasma for Patients With Colon Cancer Completed NCT01681472 Phase 1, Phase 2 6R-MTHF 200 mg/m2;Levoleucovorin 200 mg/m2;6R-MTHF 60 mg/m2;Levoleucovorin 60 mg/m2
32 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
33 Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors Completed NCT01177007 Phase 2
34 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
35 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
36 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
37 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
38 A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
39 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
40 A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
41 Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
42 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
43 Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma Completed NCT00006039 Phase 2
44 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
45 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
46 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
47 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
48 MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
49 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
50 A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Recruiting NCT03891784 Phase 2 Abemaciclib

Search NIH Clinical Center for Intestinal Benign Neoplasm

Cochrane evidence based reviews: intestinal neoplasms

Genetic Tests for Intestinal Benign Neoplasm

Anatomical Context for Intestinal Benign Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Intestinal Benign Neoplasm:


MalaCards organs/tissues related to Intestinal Benign Neoplasm:

Testes, Colon, T Cells, Liver, Small Intestine, Lung, Thyroid

Publications for Intestinal Benign Neoplasm

Articles related to Intestinal Benign Neoplasm:

(show top 50) (show all 145)
# Title Authors PMID Year
Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. 54 61
17047044 2006
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. 54 61
12460911 2002
Large esophageal schwannoma: En-bloc resection with primary closure by esophagoplasty. 61
31351369 2019
Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. 61
30307656 2018
Heterozygosity of Chaperone Grp78 Reduces Intestinal Stem Cell Regeneration Potential and Protects against Adenoma Formation. 61
30232220 2018
The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia. 61
29741675 2018
Transmission of a common intestinal neoplasm in zebrafish by cohabitation. 61
29023774 2018
Primary neoplasms of the small bowel at CT: a pictorial essay for the clinician. 61
29461587 2018
Hypothesis: Induction of biomarkers for detection of colonic neoplasms. 61
29290782 2018
A Peutz-Jeghers syndrome family associated with sinonasal adenocarcinoma: 28 years follow up report. 61
28391433 2017
Burkitt lymphoma as a lead point for jejunojejunal intussusception in a human immunodeficiency virus patient. 61
28523628 2017
Intestinal cancer stem cells marked by Bmi1 or Lgr5 expression contribute to tumor propagation via clonal expansion. 61
28176811 2017
Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factor-beta signaling in mouse intestinal neoplasms. 61
27790711 2017
Altered T-Cell Balance in Lymphoid Organs of a Mouse Model of Colorectal Cancer. 61
27798287 2016
[Application of magnetic resonance enterography for diagnosis of small intestinal diseases in children]. 61
26791925 2016
Immunohistochemical characterization of intestinal neoplasia in zebrafish Danio rerio indicates epithelial origin. 61
26503773 2015
One stage curative resection of double intestinal neuroendocrine tumors with thirty-two bilobar liver metastases. A case report. 61
26344670 2015
27159470 2015
Foot infection by Clostridium sordellii: case report and review of 15 cases in France. 61
25609723 2015
Recent advances in intestinal lymphomas. 61
25639480 2015
The hierarchical model of stem cell genesis explains the man mouse paradox, Peto's paradox, the red cell paradox and Wright's enigma. 61
25459141 2014
Polypoid arteriovenous malformation presenting with jejunojejunal intussusceptions in an adult. 61
25505727 2014
A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. 61
23943231 2014
Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. 61
24590763 2014
Pediatric ileoileal intussusception with a lipoma lead point: a case report. 61
24760240 2014
Pediatric and adult celiac disease: similarities and differences. 61
23715643 2013
Candidate serum biomarkers for early intestinal cancer using 15N metabolic labeling and quantitative proteomics in the ApcMin/+ mouse. 61
23924158 2013
Genetic control of intestinal stem cell specification and development: a comparative view. 61
22529012 2012
Monoallelic silencing and haploinsufficiency in early murine intestinal neoplasms. 61
22308460 2012
Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. 61
24714149 2012
Alginate-folic acid-modified chitosan nanoparticles for photodynamic detection of intestinal neoplasms. 61
21163518 2011
C57BL/KsJ-db/db-Apc mice exhibit an increased incidence of intestinal neoplasms. 61
22174655 2011
Diffuse infantile hemangiomatosis of the ileum presenting with multiple perforations: a case report and review of the literature. 61
20850639 2010
[Clinicopathological features of small intestinal tumors]. 61
20716865 2010
Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. 61
20348907 2010
Surgical treatment of small bowel neoplasms. 61
20496543 2010
Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. 61
19777566 2010
PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1. 61
19232344 2009
TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. 61
19208363 2009
The epidemiology and pathogenesis of neoplasia in the small intestine. 61
19064190 2009
N-Methyl-N-Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studies. 61
18827072 2008
Primary melanoma of small intestine masquerading as gastrointestinal stromal tumor: a case report and literature review. 61
18453296 2008
Colorectal cancer risk in Crohn's disease. 61
18350616 2008
[Clinical analysis of primary small intestinal neoplasms in 305 cases]. 61
18396694 2007
Carcinoid tumors are 15 times more common in patients with Crohn's disease. 61
17538985 2007
[A rare cause of bleeding intestinal intussusception in adult: jejunal lipoma]. 61
17978901 2007
Effect of dietary resistant starch and protein on colonic fermentation and intestinal tumourigenesis in rats. 61
17166881 2007
Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. 61
17598963 2007
Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. 61
15961883 2005
Detection of alkaline sphingomyelinase activity in human stool: proposed role as a new diagnostic and prognostic marker of colorectal cancer. 61
15824156 2005

Variations for Intestinal Benign Neoplasm

Expression for Intestinal Benign Neoplasm

Search GEO for disease gene expression data for Intestinal Benign Neoplasm.

Pathways for Intestinal Benign Neoplasm

Pathways related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.23 TP53 MIR20A MIR18A MIR17
Show member pathways
8 11.98 TP53 KRAS CTNNB1 APC
10 11.89 TP53 MIR21 MIR20A MIR192 MIR18A MIR17
12 11.75 TP53 KRAS HRAS CTNNB1
14 11.67 MIR20A MIR18A MIR17
16 11.59 TP53 KRAS HRAS
17 11.55 TP53 KRAS HRAS
18 11.52 TP53 KRAS HRAS
20 10.71 KRAS HRAS

GO Terms for Intestinal Benign Neoplasm

Cellular components related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 MIR532 MIR21 MIR20A MIR192 MIR18A MIR17
2 beta-catenin destruction complex GO:0030877 9.26 CTNNB1 APC
3 Wnt signalosome GO:1990909 9.16 CTNNB1 APC
4 extracellular vesicle GO:1903561 9.02 MIR21 MIR20A MIR192 MIR17 MIR15A

Biological processes related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 TP53 MIR21 KRAS HRAS CTNNB1
2 positive regulation of apoptotic process GO:0043065 9.97 TP53 MIR21 MIR15A CTNNB1 APC
3 negative regulation of cell proliferation GO:0008285 9.85 TP53 MIR21 MIR15A HRAS CTNNB1 APC
4 negative regulation of inflammatory response GO:0050728 9.81 MIR20A MIR15A MIR145 MIR142
5 negative regulation of gene expression GO:0010629 9.8 TP53 MIR21 MIR20A MIR17 HRAS CTNNB1
6 Ras protein signal transduction GO:0007265 9.79 TP53 KRAS HRAS
7 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.74 MIR21 MIR20A MIR17
8 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.67 MIR21 MIR20A MIR145
9 negative regulation of sprouting angiogenesis GO:1903671 9.65 MIR20A MIR18A MIR17
10 negative regulation of angiogenesis GO:0016525 9.65 MIR21 MIR15A MIR145 MIR143 CTNNB1
11 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.63 MIR20A MIR17
12 negative regulation of vascular endothelial growth factor production GO:1904046 9.63 MIR20A MIR17 MIR15A
13 positive regulation of metalloendopeptidase activity GO:1904685 9.61 MIR21 MIR17
14 angiotensin-activated signaling pathway GO:0038166 9.61 MIR145 MIR143
15 endothelial tube morphogenesis GO:0061154 9.6 MIR21 CTNNB1
16 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.59 MIR21 MIR17
17 response to isolation stress GO:0035900 9.58 KRAS HRAS
18 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.58 MIR21 MIR20A MIR143
19 aorta smooth muscle tissue morphogenesis GO:0060414 9.56 MIR145 MIR143
20 negative regulation of interleukin-21 biosynthetic process GO:0045391 9.55 MIR21 MIR192
21 miRNA mediated inhibition of translation GO:0035278 9.55 MIR21 MIR20A MIR17 MIR15A MIR145
22 negative regulation of interleukin-21 production GO:0032705 9.54 MIR21 MIR192
23 regulation of phenotypic switching GO:1900239 9.52 MIR145 MIR143
24 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.43 MIR145 MIR143
25 gene silencing by miRNA GO:0035195 9.36 MIR532 MIR21 MIR20A MIR192 MIR18A MIR17
26 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.13 MIR20A MIR17 MIR143

Molecular functions related to Intestinal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR21 MIR20A MIR192 MIR18A MIR17 MIR15A
2 RNA polymerase II complex binding GO:0000993 9.13 MIR20A MIR145 MIR139

Sources for Intestinal Benign Neoplasm

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....